RANKL and OPG are dysregulated in a wide range of tumors and bone metastases, mostly via induction of RANKL by tumor-derived factors such as parathyroid hormone-related protein (PTHrP) and tumor-associated suppression of OPG production or activity [11], [12]. The gene discussed is PTHLH; the disease is neoplasm.